<DOC>
	<DOCNO>NCT03097029</DOCNO>
	<brief_summary>Patients short bowel syndrome high mortality rate mainly attribute complication central line long-term intravenous ( IV ) nutrition . There medical therapy date improve gut absorption patient short bowel syndrome . The primary objective study evaluate absorption GI tract improve subject short bowel syndrome follow therapy pancreatic enzyme .</brief_summary>
	<brief_title>Use Pancreatic Enzymes Short Bowel Syndrome</brief_title>
	<detailed_description>This interventional study subject short bowel syndrome determine enteral absorption improve follow therapy pancreatic enzyme . The study assess enteral absorption nutritional status baseline series stool test , blood test , anthropometric measurement . Following approximately ten day therapy pancreatic enzyme , study reassess enteral absorption .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<criteria>history small bowel resection subsequent dependence parenteral nutrition least three month age 4 year 65 year usual state health past two week medication change able participate study four week four study visit able take pancreatic enzyme medication orally significant disease short bowel syndrome affect gastrointestinal tract impact absorption digestion motility disorder medication directly alter fat absorption cholestatic liver disease define serum conjugate bilirubin great 1.0 mg/dL , chronic renal failure , gout , hyperuricemia history pork allergy woman pregnant lactate history fibrosing colonopathy Those subject eligible malabsorption blood test ( MBT ) test exclude history soy safflower oil allergy .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pancreatic enzyme</keyword>
</DOC>